Uploaded By:  Nathanielle Punay Submitted By:  Nathanielle Punay Case Study:  No The RA was also extended to end July. Hyflux’s white knight investor Utico has announced that they raised the embattled water firm’s equity valuation offer to a minimum of $485m, a press release revealed. The UAE-based firm stated that this includes cash and stock deals, details of which have been sent to Hyflux and all creditor parties. Further, the restructuring agreement (RA) has been extended to end July, for closing by 30 August as discussed with Hyflux and its stakeholders during their 25 June stakeholders’ meeting. read more

Uploaded By:  Nathanielle Punay Submitted By:  Nathanielle Punay Case Study:  No This marks as the highest monthly sales inked since July 2018. HDB resale transactions skyrocketed 573.6% MoM and 26.7% YoY to 2,452 deals in June, according to an SRX report. About 40.3% of the volume comes from four-room, 26.3% from three-room, 24.1% from five-room, 7.4% from executive and the rest are from two-room. read more

Uploaded By:  Janine Ballesteros Submitted By:  Janine Ballesteros Case Study:  No Biolidics will be LC-Bio's exclusive partner in China for five years. Biolidics has entered into a collaboration agreement with LC-Bio Technologies, Hangzhou (LC-Bio) to develop cancer diagnostic solutions for a duration of five years, according to an announcement. Biolidics will be LC-Bio's exclusive partner in China for the development of the solutions at LC-Bio's medical laboratory located in Hangzhou. It will be using Biolidics’ proprietary circulating tumour cell technology . read more